Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZPR Regimen in R/R DLBCL
NCT05940051Phase 2Recruiting
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in diffuse large B-cell lymphoma (DLBCL). Primary endpoint: Objective Response Rate. Started Jul 2023; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05940051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05940051.